Servier Pharmaceuticals, a U.S. subsidiary of the global French pharmaceutical company Servier Group, officially opened its American headquarters, expanding its...
Shanghai Junshi Biosciences and Coherus BioSciences announced positive results of a final analysis of overall survival from the pivotal study JUPITER-02 (NCT03581786), a randomized, double-blind, placebo-controlled Phase III clinical trial evaluating Tuoyi (toripalimab in combination with gemcitabine and cisplatin) as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma
Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS) : DESTINY PWS/C601 :The study did not meet its primary endpoint of change from baseline in hyperphagia. The change was measured by the total score of a Hyperphagia Questionnaire for Clinical Trials (HQ-CT, 0?36).
Soleno Therapeutics, Inc. announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS)
Zafgen announced positive efficacy results from the bestPWS ZAF-311 study, a pivotal, double-blind, placebo-controlled Phase III trial evaluating the safety...
Alcobra Ltd. and Arcturus Therapeutics, Inc., a privately held biotechnology company developing novel RNA medicines, announced the signing of a...
Soleno Therapeutics, Inc., announced top-line results from the Company’s ongoing open-label extension study, C602, evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets for patients with Prader-Willi syndrome (PWS) and its comparison to data from the PATH for PWS natural history study.
GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOTEN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer
Royal Philips has announced that it won CE Mark approval in the European Union for its Philips V60 Plus ventilator...